This Clinical-Stage Biotech's Tackling a Huge Health Issue, but It Has to Overcome Pessimistic Investors First [The Motley Fool]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: The Motley Fool
If this company has its way, then heart disease may soon have a new enemy. Over 600,000 Americans die every year because of heart disease, and those deaths are often due to patients failing to achieve their bad cholesterol target despite taking statins. In a bid to change that, Esperion Therapeutics ( NASDAQ:ESPR ) is developing bempedoic acid, a drug that lowers cholesterol in an entirely new way. So far, bempedoic acid's trials show it effectively reduces bad cholesterol levels, but Esperion Therapeutics' stock price has been waylaid by safety concerns. Can Esperion Therapeutics overcome worry over its safety and reshape the heart disease prevention market? IMAGE SOURCE: GETTY IMAGES. What's at stake Over one-fifth of Americans between ages 40 to 75 take statins to lower their bad cholesterol, but millions of patients discontinue using these drugs because of side effects, or they fail to see their cholesterol levels drop to desirable levels. Because stati
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion to Report First Quarter 2024 Financial Results on May 7 [Yahoo! Finance]Yahoo! Finance
- Esperion to Report First Quarter 2024 Financial Results on May 7GlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity [Yahoo! Finance]Yahoo! Finance
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityGlobeNewswire
ESPR
Earnings
- 2/27/24 - Beat
ESPR
Sec Filings
- 4/11/24 - Form DEF
- 4/11/24 - Form ARS
- 3/15/24 - Form 4
- ESPR's page on the SEC website